Fabege AB (0XPX)
London Exchange · UK · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 64.88 |
|---|---|
| 52-week range | 62.80 – 88.10 |
| Return, 1 month / 3 months | −5.3% / −12.3% |
| Return, 1 year / 3 years | −25.8% / −12.4% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 19.9% |
| Worst drawdown (1 year) | -26.6% |
| Average daily value traded | 3.92M SEK |
| Dividend yield | 0.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Fabege AB is a Swedish property company that owns, manages and develops commercial real estate, chiefly office buildings, in and around Stockholm. Its customers are businesses and organisations that lease office space, and the company also takes part in urban development projects that create new workplaces and mixed-use districts. Its properties are concentrated in established and emerging business areas of the Swedish capital region, where it lets space and manages buildings over the long term.
On this site Fabege AB appears as a stock on the London Exchange (UK), code 0XPX, with prices in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Fabege AB (0XPX) trades on the London Exchange in UK. It last closed at SEK 64.88 on 23 October 2026.
Its price-based Market X-Ray is 42 out of 100 (a weak price profile), ranking 2,513 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 25.8% and over the last three months it fell 12.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 26 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -14.7% | ||
| From 52-week high | -26.3% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -12.3% | ||
| 6-month return | -16.0% | ||
| 12-month return, skipping the last month | -21.7% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 19.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.6% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.92M SEK | ||
| Zero-volume days | 8.3% | ||
| Income | 26 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.8% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.3% |
|---|---|
| 1 month | −5.3% |
| 3 months | −12.3% |
| 6 months | −16.0% |
| 1 year | −25.8% |
| 3 years | −12.4% |
| 5 years | −49.7% |
Signals
| 50-day / 200-day average | 69.13 / 76.09 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.04 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jan 2026 | SEK 0.5000 |
| 10 Oct 2025 | SEK 0.5000 |
| 11 Jul 2025 | SEK 0.5000 |
| 24 Apr 2025 | SEK 0.5000 |
| 7 Jan 2025 | SEK 0.4500 |
| 3 Oct 2024 | SEK 0.4500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.